Stryker Co. (NYSE:SYK) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. decreased its position in Stryker Co. (NYSE:SYK - Free Report) by 18.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 144,391 shares of the medical technology company's stock after selling 32,906 shares during the period. Adage Capital Partners GP L.L.C.'s holdings in Stryker were worth $51,988,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SYK. Sompo Asset Management Co. Ltd. lifted its stake in shares of Stryker by 1.7% during the 4th quarter. Sompo Asset Management Co. Ltd. now owns 2,360 shares of the medical technology company's stock worth $850,000 after purchasing an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC raised its holdings in Stryker by 16.2% in the fourth quarter. Coppell Advisory Solutions LLC now owns 1,652 shares of the medical technology company's stock worth $600,000 after purchasing an additional 230 shares in the last quarter. Mar Vista Investment Partners LLC lifted its position in shares of Stryker by 15.8% during the fourth quarter. Mar Vista Investment Partners LLC now owns 81,834 shares of the medical technology company's stock valued at $29,464,000 after buying an additional 11,155 shares during the last quarter. CSM Advisors LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $202,000. Finally, Brasada Capital Management LP grew its position in shares of Stryker by 805.2% in the 4th quarter. Brasada Capital Management LP now owns 17,190 shares of the medical technology company's stock worth $6,205,000 after buying an additional 15,291 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Shares of NYSE:SYK traded up $1.52 during trading on Monday, hitting $366.58. 1,223,251 shares of the stock traded hands, compared to its average volume of 1,356,505. The company has a fifty day moving average price of $367.81 and a two-hundred day moving average price of $373.43. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market cap of $139.92 billion, a price-to-earnings ratio of 47.24, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 earnings per share. As a group, equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's dividend payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Argus set a $450.00 price objective on shares of Stryker in a research report on Monday, February 3rd. Finally, BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $423.53.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.